Most macrolides penetrate and persist in peripheral tissues, irrespective of plasma concentrations. For this reason, comparative pharmacodynamics of macrolides might be better based on tissue rather than plasma pharmacokinetics. The present study compares the antimicrobial effects of azithromycin and roxithromycin on Streptococcus pyogenes and Streptococcus pneumoniae using in vitro simulations of steady-state pharmacokinetics in human tonsils expected after a third 500 mg dose of azithromycin administered once a day and after a sixth 150 mg dose of roxithromycin administered twice a day. Clinical isolates of S. pyogenes and S. pneumoniae (MICs 0.12 and 0.47 mg/L of azithromycin, and 0.15 and 0.60 mg/L of roxithromycin, respectively) were used. More pronounced antistreptococcal effects were observed with azithromycin than with roxithromycin. Despite similar rates of initial killing of S. pyogenes and S. pneumoniae, the respective 12 h areas between the control growth curve and the time-kill curve of antibiotic-exposed bacteria (ABBCs) were 22% and 36% greater with azithromycin than roxithromycin. Moreover, with azithromycin, viable bacterial counts reached the theoretically achievable limit of detection (10 cfu/mL) 8-10 h after drug administration, with no regrowth within 48 h. In contrast to azithromycin, S. pyogenes and S. pneumoniae exposed to roxithromycin regrew 26 and 6 h, respectively, after initial reduction of the starting inoculum. Further in vitro simulations of tissue pharmacokinetics might be useful for pharmacodynamic comparisons among other macrolides.
Introduction
Most macrolides introduced over the past decade exhibit an enhanced ability to penetrate and persist in peripheral tissues, irrespective of high (e.g. roxithromycin, clarithromycin) or relatively low (e.g. azithromycin, dirithromycin) plasma concentrations. 1 Therefore, as a measure of tissue availability, the ratio of the area under the concentration-time curve (AUC) in peripheral tissue to the respective AUC in plasma differs among the macrolides. For example, the tissue availability of azithromycin is 55-fold higher in tonsils (17. 7) 2 and six-fold higher in sinus mucosa (6.2) 2 than roxithromycin (0.32 3 and 0.95, 4 respectively). These differences relate to comparable peak concentrations in tonsils and sinus with both drugs, despite lower azithromycin plasma concentrations, [2] [3] [4] and help to explain the similar clinical efficacy of the two macrolides in upper respiratory tract infections. 5 Similarities or differences in efficacy between these two macrolides might better correlate with their tissue concentrations than their plasma concentrations. Furthermore, a true understanding of comparative macrolide pharmacodynamics should be based on appropriate in vitro simulations of tissue rather than plasma pharmacokinetics, as 
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Materials and methods
Antimicrobial agents and bacterial strains
Azithromycin and roxithromycin powders were kindly provided by Roerig, a division of Pfizer Pharmaceuticals, (Groton, CT, USA) and Hoechst-Marion-Roussel (Bridgewater, NJ, USA), respectively. Clinical isolates of Streptococcus pyogenes and Streptococcus pneumoniae with similar susceptibility to both macrolides were used in the study. MICs determined by multiple serial dilutions were 0.12 and 0.47 mg/L of azithromycin and 0.15 and 0.60 mg/L of roxithromycin, respectively.
Simulated pharmacokinetic profiles
The simulated pharmacokinetic profiles reflected steadystate tonsillar concentrations of the macrolides expected after a third dose of azithromycin 500 mg od and after a sixth dose of roxithromycin 150 mg bd.
Azithromycin. To calculate the steady-state concentrations of azithromycin in human tonsils, pharmacokinetic data from a 500 mg single dose study 2 and a study that used two 250 mg doses administered 12 hourly 8 were combined. The first study measured azithromycin concentrations in homogenized tonsils from 1 to 12 h post-dose, whereas the second study used data obtained between 13 and 178 h, without reference to the ascending limb of the concentration-time curve (Figure 1a) . The combined data set was fitted by the Bateman function:
where C(t) is the drug concentration in the tonsils at the time t after administration, k in and k el are the rate constants of drug input and elimination, respectively, and A and B are coefficients. The lag-time (T lag ) of drug appearance in the tonsils was calculated by the equation:
Best fit estimates of these parameters obtained by a nonlinear regression analysis using TopFit software [v. 1.1, Godecke (Freiburg), Schering (Berlin) and Thomae (Biberachan-den-Riss, Germany)] are shown in the Table. Assuming linear pharmacokinetics and using the superimposition principle, steady-state tonsillar concentrations of azithromycin were calculated based on the parameters of equation 1. The pharmacokinetic profile that can be expected over a 48 h time period after the third daily 500 mg dose of azithromycin is shown in Figure 1b . This profile is presented as the sum of the two superimposed profiles. One of these represents the mono-exponential time course of residual azithromycin concentrations following the preceding, i.e. second dose. The other represents azithromycin pharmacokinetics after a single 500 mg dose. These two profiles, simulated simultaneously, provide the net pharmacokinetic profile that mimics the third administration of azithromycin (see below). 
In vitro dynamic model
A slightly modified version of a previously described dynamic model 9 was used. Pharmacokinetically, the model consists of two compartments: subcompartment 0, which mimics mono-exponential drug efflux from the systemic circulation to tonsillar tissue; and compartment 1, which mimics drug pharmacokinetics in tonsils, obeying the Bateman function. Mono-exponential efflux of antibiotic is provided by continuous dilution of antibiotic solution of volume in subcompartment 0 (V 0 ) with fresh nutrient medium with a flow rate F. Bi-exponentially changing concentrations of antibiotic in compartment 1 of volume V 1 are provided by continuous influx of antibiotic solution in nutrient medium from subcompartment 0 and by efflux of antibiotic solution from compartment 1 to the waste with the same flow rate F. Based on azithromycin and roxithromycin pharmacokinetic parameters, F, V 0 and V 1 were calculated as described elsewhere. 10 The respective values of F, V 0 and V 1 are presented in the Table. To simulate the mono-exponential decay of residual antibiotic concentrations from the preceding dose, azithromycin or roxithromycin was administered into compartment 1 to achieve the desired level (8.4 and 1.0 mg/L, respectively). To simulate the lag-time in tonsillar drug appearance, antibiotics were administered into subcompartment 0 1 h after their administration into compartment 1.
Physically, the model was represented by three connected flasks: one containing fresh trypticase soy broth with 10% pooled horse serum; the second, subcompartment 0, containing the same broth; and the third, compartment 1, containing the broth plus a bacterial culture (Figure 2 ). The third flask had a magnetic stirrer and was incubated at 37ЊC. The system was filled with sterile broth. The medium in the third flask was inoculated with a 24 h culture of S. pyogenes or S. pneumoniae, and after a further 2 h incubation, when exponentially growing cultures approached c. 10 6 cfu/mL, azithromycin or roxithromycin was injected into the third flask and 1 h later into the second flask. Peristaltic pumps circulated fresh nutrient medium from the first flask to the second flask and then to the third flask, as well as from the third flask to the waste chamber.
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Table. Parameters of equations 1 and 2, and those of the dynamic model 
A. A. Firsov et al.
The volumes of fluids in the second and third flasks were maintained constant during the experiment.
Validation of the dynamic model
The ability of the dynamic model to simulate the required pharmacokinetic profiles of azithromycin and roxithromycin was tested using ciprofloxacin, because levels of this drug can be measured easily with good reliability and sensitivity. The pharmacokinetic parameters of azithromycin and roxithromycin were produced in the model in triplicate using ciprofloxacin. To verify the suitability of the use of ciprofloxacin as a marker for the macrolides, parallel determinations of ciprofloxacin and roxithromycin were also performed when 10-fold greater concentrations of roxithromycin and ciprofloxacin with pharmacokinetic parameters of roxithromycin were simulated simultaneously.
Assays
Ciprofloxacin concentrations were assayed by highperformance liquid chromatography (HPLC) with a precolumn (50 ϫ 4.6 mm) and on a column (250 ϫ 4.6 mm) of Silasorb 5 C 8 (Lachema, Czech Republic). The mobile phase was 0.02 M KH 2 PO 4 , ethanol and acetonitrile (70:20:10 v/v), pumped at a flow rate of 1.3 mL/min. Fluorometric detection (274 nm excitation, 418 nm emission) was used. The detection limit was 0.05 mg/L. The calibration curve was linear within the range 0.1-20 mg/L, and the coefficients of variation at ciprofloxacin 10 and 1 mg/L were 2.2% and 3.4%, respectively. Roxithromycin concentrations were also determined by HPLC using a precolumn (50 ϫ 4.6 mm) and on a column (250 ϫ 4 mm) with Nucleosil 10 C 18 (Macherey-Nagel, Germany). The mobile phase consisted of acetonitrile and 0.067 M phosphate buffer pH 4 (45:55 v/v), pumped at a flow rate of 1.1 mL/min. Detection was by UV absorption at 210 nm. The calibration curve was linear for roxithromycin concentrations ranging from 1 to 20 mg/L, the limit of detection was 0.5 mg/L and the coefficient of variation at roxithromycin 10 mg/L was 2.4%.
Quantification of bacterial growth and killing
In each experiment, 0.1 mL samples were withdrawn from bacteria-containing media in the central compartment (the third flask) throughout the observation period, initially every hour, then every 3 h, and again hourly during the last 6-7 h. These samples were subjected to serial 10-fold dilutions with chilled, sterile 0.9% NaCl and were plated in duplicate on trypticase soy agar supplemented with 10% pooled horse serum. After overnight incubation at 37ЊC in a 5% CO 2 atmosphere, the resulting bacterial colonies were counted, and the numbers of cfu/mL were calculated.
The limit of accurate quantification was 2 ϫ 10 2 cfu/mL. A level of 10 cfu/mL was considered a theoretically achievable limit of detection.
The bacterial elimination rate constant (k elb ) as a measure of the rate of initial killing was determined as described elsewhere. 11 The area between the control growth curve and the time-kill curve of antibiotic-exposed bacteria (ABBC) 12 as an integral measure of the antimicrobial effect was determined over the first 12 h (Figure 3) .
Results
Pharmacokinetic validation of the dynamic model
The suitability of ciprofloxacin as a marker for the macrolides was verified by simultaneous simulation of roxithromycin and ciprofloxacin with the pharmacokinetic parameters of roxithromycin. As seen in Figure 4a , the concentrations of ciprofloxacin in compartment 1 of the dynamic model matched those of roxithromycin. This validated the use of ciprofloxacin alone in the further model validation experiments. As seen in Figure 4 (b and c) , the concentrations of ciprofloxacin determined with the pharmacokinetic parameters of azithromycin and roxithromycicn were close to the expected pharmacokinetic profiles.
Azithromycin and roxithromycin pharmacodynamics
The time-kill kinetics of S. pyogenes and S. pneumoniae exposed to the macrolides and the respective control growth curves are presented in Figure 5 . Azithromycin Figure 3 . Determination of ABBC applied to the kinetics of the killing of S. pyogenes exposed to azithromycin. ABBC describes the shaded area between the control growth and the killing and regrowth curves, limited from above by a cut-off level of 10 9 cfu/mL and from below by the theoretical limit of detection (10 cfu/mL).
produced rapid killing of S. pyogenes and S. pneumoniae, with no regrowth for at least 48 h; the viable counts reached the theoretical limit of detection 8-10 h after drug administration. In contrast to azithromycin, S. pyogenes and S. pneumoniae exposed to roxithromycin regrew 26 or 6 h, respectively, after initial rapid reduction of the starting inoculum. The differences between the antimicrobial effects of azithromycin and roxithromycin can be seen over the first 12 h, i.e. within the dosing interval of roxithromycin. Using ABBC as an endpoint of the antimicrobial effect, azithromycin is 22% more efficient against S. pyogenes and 36% more efficient against S. pneumoniae than roxithromycin (ABBC of 78 versus 64, and 72 versus 53 log cfu/mL·h, respectively). However, the rates of azithromycin-and roxithromycin-induced killing were similar-with S. pyogenes the respective k elb s were 1.4/h and 1.3/h, and with S. pneumoniae the k elb s were 1.3/h and 1.5/h, respectively.
Discussion
In vitro simulations of tissue pharmacokinetics are relatively rare. Usually, such simulations are associated with dialysis models that expose bacteria to antibiotic in peripheral compartments where the observed pharmacokinetic profiles may approximate the time course of antibiotic concentrations in a peripheral compartment of a pharmacokinetic model, but they are not usually attributed to a specific tissue. 10 The present study demonstrates an alternative approach to in vitro simulations in which specific tonsillar pharmacokinetic profiles are simulated directly in the central compartment (compartment 1) of the dynamic model. The reliability of these simulations was verified by using ciprofloxacin to mimic the pharmacokinetic parameters of azithromycin and roxithromycin, since it was a compound that could be easily assayed. The measured concentrations were close to the expected target concentrations. Unfortunately, the realities of in vitro simulations of specific tissue pharmacokinetics are limited by the availability of in vivo data: all too often, reported tissue concentrations are too sparse to allow appropriate model fitting. Paradoxically, this applies to the new macrolides, although their excellent tissue penetration was a major driving force in their development. Moreover, most in vivo studies, including those used as a basis for our in vitro simulations, report macrolide concentrations in homogenized tissues, i.e. the sum of relatively high interstitial and relatively low extracellular concentrations, which are in a dynamic equilibrium with plasma concentrations of free (i.e. non-protein-bound) drug. 13 Although extracellular concentrations of macrolides are considered more predictive of their antimicrobial effect on most common respiratory tract pathogens, 14 this may not explain reported similar efficacies of azithromycin, roxithromycin and clarithromycin in upper respiratory tract infections, 5, 15 and azithromycin and clarithromycin in streptococcal tonsillitis, 15 despite the markedly lower extracellular concentrations of azithromycin.
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This study demonstrated the more pronounced antimicrobial effects of simulated tonsillar concentrations of azithromycin compared with those of roxithromycin against S. pyogenes and S. pneumoniae. Despite similar rates of initial killing, the antibacterial effects as expressed by the ABBC determined over the first 12 h of antibiotic exposure were 22% and 36% greater with azithromycin than with roxithromycin, respectively. Moreover, no regrowth occurred with S. pyogenes and S. pneumoniae exposed to azithromycin, but bacterial regrowth was observed 26 or 6 h, respectively, after administration of roxithromycin.
Clearly, these differences would not have been seen with an in vitro simulation of plasma concentrations of these macrolides, which are much higher with roxithromycin than azithromycin. In this light, the more pronounced killing of bacteria exposed to plasma concentrations of clarithromycin compared with azithromycin reported by Bauernfeind et al. 6 is quite predictable, because the simulated peak concentration-to-MIC ratios were 5-20 times higher for clarithromycin with four of the five organisms studied. Other conclusions might have been drawn if peripheral tissue pharmacokinetics of clarithromycin and azithromycin were simulated.
Overall, the results of pharmacodynamic comparisons among the tissue-selective macrolides might be highly dependent on whether systemic or peripheral pharmacokinetics are simulated. Care must be taken in deciding which model is most relevant to the clinical situation.
